Sunshine Heart (CHFS) Upgraded by Zacks Investment Research to “Buy”
Zacks Investment Research upgraded shares of Sunshine Heart (NASDAQ:CHFS) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. Zacks Investment Research currently has $4.00 target price on the stock.
According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “
Separately, ValuEngine downgraded shares of Sunshine Heart from a sell rating to a strong sell rating in a report on Monday, October 2nd.
Sunshine Heart (NASDAQ:CHFS) last announced its earnings results on Tuesday, October 31st. The company reported ($4.55) EPS for the quarter. Sunshine Heart had a negative return on equity of 165.61% and a negative net margin of 263.73%. research analysts forecast that Sunshine Heart will post -3.03 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/01/21/sunshine-heart-chfs-upgraded-by-zacks-investment-research-to-buy.html.
About Sunshine Heart
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.